CoreCap Advisors’s Neurogene NGNE Stock Holding History

CoreCap Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$111	Buy	+4	New	+$143	﹤0.01%	3036
2025 Q2	–	Sell	-11	Closed	-$129	–	3069
2025 Q1	$129	Hold	11	–	–	﹤0.01%	3041
2024 Q4	$251	Buy	+11	New	+$409	﹤0.01%	2690

Other funds holding NGNE

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

CoreCap Advisors's NGNE Position: Q3 2026 in Review

CoreCap Advisors opened a new position in Neurogene (NGNE) in Q3 2026: 4 shares worth $111. The stake represents ﹤0.01% of the portfolio and ranks #3036 among its holdings. This is a return to the name: CoreCap Advisors previously reported a position in NGNE as recently as Q1 2025.

CoreCap Advisors first reported a position in NGNE in Q4 2024 and has held it in 3 quarters since. The position peaked at $251 in Q4 2024. 8 funds tracked by Wall St. Rank hold NGNE as of Q3 2026.

CoreCap Advisors held 4 shares of Neurogene worth $111 as of Q3 2026.
Neurogene was a new CoreCap Advisors position in Q3 2026.
Neurogene made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #3036 holding.
CoreCap Advisors first reported a position in Neurogene in Q4 2024 and has held it in 3 quarters since.
CoreCap Advisors's Neurogene position peaked at $251 in Q4 2024.
8 funds tracked by Wall St. Rank held Neurogene as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.